Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb and 2seventy bio, Inc. today announced the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee will meet to review data supporting the supplemental...